Anika shareholders approve 250,000-share increase in 2017 incentive plan, reelect directors

Anika Therapeutics, Inc.

Stockholders approved amendment increasing shares under 2017 Omnibus Plan from 4.6M to 4.85M; 10.1M in favor, 2.25M against.
Cheryl R. Blanchard (Ph.D.) reelected as Class II director with 11.36M votes for, 1.11M against; Glenn R. Larsen (Ph.D.) with 11.98M for, 0.32M against.
Ratification of Deloitte & Touche as auditor passed with 13.13M for, 0.08M against, 15.3K abstain; advisory say-on-pay passed with 12.15M for.
Meeting turnout: 13.22M shares present (91.07% of voting power).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.